Chronic Kidney Disease Clinical Trial
Official title:
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Using Cinacalcet to Correct Hypercalcemia in Renal Transplant Recipients With Autonomous Hyperparathyroidism
Verified date | September 2018 |
Source | Amgen |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Hyperparathyroidism (HPT) is common in people with a kidney transplant. Patients with HPT often have high parathyroid hormone (PTH) levels and may have large parathyroid glands in the neck. Patients with HPT can develop bone disease (osteodystrophy). This bone disease can cause bone pain, fractures, and poor formation of red blood cells. Other problems from HPT may include increases in blood levels of calcium (hypercalcemia) and low blood levels of phosphorus (hypophosphatemia). The high calcium levels may cause calcium to deposit in body tissues. Calcium deposits can cause arthritis (joint pain and swelling), muscle inflammation, itching, gangrene (death of soft tissue), heart and lung problems or kidney transplant dysfunction (worsening of kidney transplant function). The purpose of this study is to evaluate the effects of cinacalcet (Sensipar/Mimpara) on high calcium levels in the blood in patients with HPT after a kidney transplant.
Status | Completed |
Enrollment | 114 |
Est. completion date | April 16, 2013 |
Est. primary completion date | September 13, 2012 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Received a kidney transplant = 9 weeks at time of Screening and = 24 months before first dose - May be the first kidney transplant or a repeat kidney transplant. - Subjects with a functional, stable kidney transplant, defined as MDRD estimated glomerular filtration rate (eGFR) = 30 mL/min/1.73 m² (chromic kidney disease stage 3 or better) at Screening. - Men or women = 18 years at the start of Screening (ie, time of informed consent). - Corrected total serum calcium > 10.5 mg/dL (2.63 mmol/L), defined as the mean of 2 values in Screening period. - iPTH > 100 pg/mL (10.6 pmol/L), during the Screening period (obtained at either Screen 1 or Screen 2). Exclusion Criteria: - Received cinacalcet therapy post-transplant for more than 14 days cumulatively post-transplant. If cinacalcet therapy was received for a total of 14 days or less post-transplant, there must be a 4-week washout before subject is eligible for screening (Note: This does not exclude pre-transplant use of cinacalcet). - Anticipated parathyroidectomy within 6 to12 months after Randomization. - Ongoing therapy with bisphosphonates or use within 6 months prior to Screening. - Ongoing use of 1,25-dihydroxyvitamin D3 (including other active vitamin D metabolites or analogues) or use within 30 days prior to Screening. - Ongoing use of calcium supplements or use within 30 days prior to Screening. - Ongoing use of phosphate binders (calcium or non-calcium containing) or use within 30 days prior to Screening. - Ongoing use of a thiazide diuretic. - Subjects with a history of seizures who had a seizure within the 3 months prior to Randomization, which required adjustments to the seizure medication. - Acute Kidney Injury (AKI) or renal biopsy within 6 weeks prior to Screening, unless it is an institutional protocol-driven biopsy. |
Country | Name | City | State |
---|---|---|---|
Australia | Research Site | Camperdown | New South Wales |
Australia | Research Site | Parkville | Victoria |
Australia | Research Site | Westmead | New South Wales |
Australia | Research Site | Woodville South | South Australia |
Austria | Research Site | Wien | |
Belgium | Research Site | Brussels | |
Belgium | Research Site | Gent | |
Belgium | Research Site | Leuven | |
Canada | Research Site | Calgary | Alberta |
Canada | Research Site | London | Ontario |
Canada | Research Site | Ottawa | Ontario |
Canada | Research Site | Toronto | Ontario |
Canada | Research Site | Vancouver | British Columbia |
France | Research Site | Bordeaux Cedex | |
France | Research Site | Montpellier cedex 05 | |
France | Research Site | Nantes Cedex 1 | |
France | Research Site | Paris Cedex 15 | |
France | Research Site | Toulouse Cedex 09 | |
Germany | Research Site | Berlin | |
Germany | Research Site | Kiel | |
Italy | Research Site | Genova | |
Italy | Research Site | Milano | |
Italy | Research Site | Padova | |
Poland | Research Site | Gdansk | |
Poland | Research Site | Katowice | |
Poland | Research Site | Lodz | |
Poland | Research Site | Poznan | |
Poland | Research Site | Szczecin | |
Spain | Research Site | Barcelona | Cataluña |
Spain | Research Site | Barcelona | Cataluña |
Spain | Research Site | L'Hospitalet de Llobregat | Cataluña |
Spain | Research Site | Málaga | AndalucÃ-a |
Spain | Research Site | Madrid | |
Switzerland | Research Site | Bern | |
Switzerland | Research Site | Geneva 14 | |
Switzerland | Research Site | Zurich | |
United States | Research Site | Atlanta | Georgia |
United States | Research Site | Aurora | Colorado |
United States | Research Site | Bethlehem | Pennsylvania |
United States | Research Site | Chicago | Illinois |
United States | Research Site | Dallas | Texas |
United States | Research Site | Detroit | Michigan |
United States | Research Site | Evanston | Illinois |
United States | Research Site | Gainesville | Florida |
United States | Research Site | Houston | Texas |
United States | Research Site | Nashville | Tennessee |
United States | Research Site | New York | New York |
United States | Research Site | Phoenix | Arizona |
United States | Research Site | San Francisco | California |
United States | Research Site | Springfield | Massachusetts |
United States | Research Site | Tempe | Arizona |
Lead Sponsor | Collaborator |
---|---|
Amgen |
United States, Australia, Austria, Belgium, Canada, France, Germany, Italy, Poland, Spain, Switzerland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of Participants With a Mean Corrected Total Serum Calcium Value < 10.2 mg/dL (2.55 mmol/L) During the Efficacy Assessment Phase (EAP) | Weeks 21 to 26 (EAP) | ||
Secondary | Percent Change From Baseline to Week 52 in Bone Mineral Density at the Femoral Neck | Bone mineral density (BMD) was measured using dual X-ray absorptiometry (DXA). | Baseline and Week 52 | |
Secondary | Change From Baseline to the EAP in Mean Serum Phosphorus | Baseline and the EAP (mean of Weeks 22, 24, and 26) | ||
Secondary | Change From Baseline to Week 52 in eGFR | eGFR was calculated using the Modification of Diet in Renal Disease (MDRD) formula. | Baseline and Week 52 | |
Secondary | Change From Baseline to the EAP in Corrected Total Calcium | Baseline and the EAP (mean of Weeks 22, 24, and 26) | ||
Secondary | Change From Baseline to the EAP in Intact Parathyroid Hormone (iPTH) | Baseline and the EAP (mean of Weeks 22, 24, and 26) | ||
Secondary | Change From Baseline to the EAP in Urine Phosphorus | Baseline and the EAP (mean of Weeks 22, 24, and 26) | ||
Secondary | Percentage of Participants With a Parathyroidectomy | 56 weeks | ||
Secondary | Time to Parathyroidectomy | 56 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05491642 -
A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses
|
Phase 1 | |
Recruiting |
NCT06363097 -
Urinary Uromodulin, Dietary Sodium Intake and Ambulatory Blood Pressure in Patients With Chronic Kidney Disease
|
||
Terminated |
NCT04043026 -
The Effects of Renal Function and Atrial Fibrillation on Lipoproteins and Clot Structure/Function
|
||
Completed |
NCT05318014 -
Low-protein Formula Supplements in Chronic Kidney Disease
|
N/A | |
Active, not recruiting |
NCT06071065 -
Clinical Pharmacist Intervention on Medication Adherence and Clinical Outcomes in Chronic Kidney Disease Patients
|
N/A | |
Completed |
NCT02878317 -
Skin Autofluorescence as a Risk Marker in People Receiving Dialysis.
|
||
Not yet recruiting |
NCT06039254 -
Safety and Pharmacokinetics of HRS-1780 in Healthy Subjects and Subjects With Impaired Renal Function
|
Phase 1 | |
Recruiting |
NCT03160326 -
The QUALITY Vets Project: Muscle Quality and Kidney Disease
|
||
Completed |
NCT02836574 -
A Study of Renal Autologous Cell Therapy (REACT) in Type 2 Diabetics With Chronic Kidney Disease
|
Phase 2 | |
Completed |
NCT02756520 -
Observational Study on CKD Treatment With a Ketosteril Supplemented Protein-restricted Diet (Keto-024-CNI)
|
||
Completed |
NCT02875886 -
DD-study: Diet or Diuretics for Salt-sensitivity in Chronic Kidney Disease
|
Phase 4 | |
Withdrawn |
NCT02885545 -
The Strategy to Prevent Hemorrhage Associated With Anticoagulation in Renal Disease Management (STOP HARM) Trial
|
Phase 4 | |
Completed |
NCT02896309 -
The Effect of Correction of Metabolic Acidosis in CKD on Intrarenal RAS Activity
|
N/A | |
Completed |
NCT02888171 -
Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With CKD and Iron Deficiency
|
N/A | |
Active, not recruiting |
NCT02483039 -
Nephrologist Follow-up Versus Usual Care After an Acute Kidney Injury Hospitalization
|
N/A | |
Completed |
NCT02369549 -
Micro-Particle Curcumin for the Treatment of Chronic Kidney Disease
|
Phase 3 | |
Completed |
NCT02992548 -
Effect of Pravastatin on Erythrocyte Membrane Fatty Acid Contents in Patients With Chronic Kidney Disease
|
Phase 4 | |
Terminated |
NCT02543177 -
Optimised Procedure in Patients With NSTEMI and CKD
|
N/A | |
Recruiting |
NCT02205944 -
Impact of Presurgical Exercise on Hemodialysis Fistula Outcomes
|
N/A | |
Active, not recruiting |
NCT02231138 -
Efficacy and Safety of Abelmoschus Manihot for Chronic Kidney Disease
|
Phase 4 |